What is Armata Pharmaceuticals Capex-to-Operating-Income?
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.
Armata Pharmaceuticals Capex-to-Operating-Income Historical Data
The historical data trend for Armata Pharmaceuticals's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Armata Pharmaceuticals Capex-to-Operating-Income Chart
Competitive Comparison of Armata Pharmaceuticals's Capex-to-Operating-Income
For the Biotechnology subindustry, Armata Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Armata Pharmaceuticals's Capex-to-Operating-Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Armata Pharmaceuticals's Capex-to-Operating-Income falls into.
Armata Pharmaceuticals Capex-to-Operating-Income Calculation
Armata Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Armata Pharmaceuticals (AMEX:ARMP) Capex-to-Operating-Income Explanation
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Armata Pharmaceuticals Capex-to-Operating-Income Related Terms
Thank you for viewing the detailed overview of Armata Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Armata Pharmaceuticals (Armata Pharmaceuticals) Business Description
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARMP has been successfully added to your 